Advanced glycation end products, galectin-3, matrix metalloproteinase-9 activity in men with heart failure and concomitant benign prostatic hyperplasia with androgen deficiency

• Published in: Medychni perspektyvy 2021-12, Vol.26 (4), p.67-73
• Main Authors: Nedzvetsky, V.S., Sirenko, O.Yu, Tkachenko, V.A., Kuryata, O.V.
• Format: Article
• Language: English
• Subjects: advanced glycation end products; Ejection fraction; Enzymes; Genital diseases; Heart failure; Hyperplasia; preserved ejection fraction; Proteins; Testosterone; testosterone deficiency
• ISSN: 2307-0404; 2786-4804
• DOI: 10.26641/2307-0404.2021.4.248094

The aim was to evaluate serum levels of matrix metalloproteinases-9 activity, advanced glycation end products, galectin-3, C-reactive protein in men with heart failure and benign prostatic hyperplasiawith testosterone deficiency. The testosterone level was determined by immune-enzyme analysis. The content of advanced glycation end products in plasma were analysed by quantitative autofluorescence. The metalloproteinases-9 activity was estimated with fluorometry. The level of galectin-3, C-reactive protein was determined by immune-enzyme analysis. 1st group was made up by the men with heart failure and benign prostatic hyperplasia with testosterone deficiency; 2nd group – by the men without testosterone deficiency. The men with heart failure and benign prostatic hyperplasia with testosterone deficiency had a significantly higher level of advanced glycation end products, galectin-3, matrix metalloproteinases-9 activity in comparison with men with heart failure without testosterone deficiency (p